Zai Lab (ZLAB) said late Wednesday the US Food and Drug Administration has granted orphan drug designation to ZL-1310 for the treatment of small cell lung cancer following data from an ongoing phase 1a/1b study.
ZL-1310 will be eligible for certain development incentives, including tax credits for certain clinical trials and the potential to receive a seven-year US market exclusivity period upon product approval, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。